Literature DB >> 16678686

Activated protein C-protein C inhibitor complex: a new biological marker for aortic aneurysms.

Tilo Kölbel1, Karin Strandberg, Ingrid Mattiasson, Johan Stenflo, Bengt Lindblad.   

Abstract

OBJECTIVE: The concentration of the complex between activated protein C (APC) and protein C inhibitor (PCI) is a measure of thrombin generation. We studied whether it can provide information useful for the diagnosis and treatment of arterial vascular disease.
METHODS: Blood was obtained from 429 vascular patients admitted consecutively during September 2004 to March 2005. The APC-PCI complex was measured by using a sandwich immunofluorometric method. The patients were divided into cohorts according to the planned treatment and compared with a control group of healthy individuals.
RESULTS: The APC-PCI complex concentration varied from 0.08 to 2.50 microg/L. In the cohort of patients with aortic aneurysms (n = 78), the median APC-PCI value was 0.45 (10th to 90th percentile, 0.24-1.47), and values were clearly increased compared with all other cohorts (P < .0001). Patients with carotid disease (n = 73) yielded a median of 0.22 (10th to 90th percentile, 0.15-0.48). The median for claudicants (n = 74) was 0.26 microg/L (10th to 90th percentile, 0.15-0.75), which was higher than in those (n = 97) with critical ischemia (0.20; 10th to 90th percentile, 0.13-0.36; P < .0023). The cohort with other forms of atherosclerotic disease (n = 40) had a median of 0.23 (10th to 90th percentile, 0.14-0.42), whereas the value for a cohort of 21 patients with venous disease was 0.19 (10th to 90th percentile, 0.10-0.34). The median was 0.15 (10th to 90th percentile, 0.10-0.23) for the control group (n = 121).
CONCLUSIONS: Patients with atherosclerosis had an increased APC-PCI concentration that corresponded to increased generation of thrombin. Patients with aortic aneurysm had a threefold higher median concentration than the control group. We suggest that this remarkable increase is caused by the local activation of coagulation, and we surmise that APC-PCI measurements can be used as a screening tool to identify patients with aortic aneurysms.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16678686     DOI: 10.1016/j.jvs.2006.01.019

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  9 in total

Review 1.  Biomarkers of AAA progression. Part 1: extracellular matrix degeneration.

Authors:  Femke A M V I Hellenthal; Willem A Buurman; Will K W H Wodzig; Geert Willem H Schurink
Journal:  Nat Rev Cardiol       Date:  2009-05-26       Impact factor: 32.419

2.  Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex.

Authors:  Wei Li; Ty E Adams; Jyoti Nangalia; Charles T Esmon; James A Huntington
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

3.  Gene expression profiling of blood in brain arteriovenous malformation patients.

Authors:  Shantel M Weinsheimer; Huichun Xu; Achal S Achrol; Boryana Stamova; Charles E McCulloch; Ludmila Pawlikowska; Yingfang Tian; Nerissa U Ko; Michael T Lawton; Gary K Steinberg; Steven D Chang; Glen Jickling; Bradley P Ander; Helen Kim; Frank R Sharp; William L Young
Journal:  Transl Stroke Res       Date:  2011-12-01       Impact factor: 6.829

Review 4.  Circulating markers of abdominal aortic aneurysm presence and progression.

Authors:  Jonathan Golledge; Philip S Tsao; Ronald L Dalman; Paul E Norman
Journal:  Circulation       Date:  2008-12-02       Impact factor: 29.690

5.  APC-PCI complex levels for screening of AAA in patients with peripheral atherosclerosis.

Authors:  Moncef Zarrouk; Kave Keshavarz; Bengt Lindblad; Anders Gottsäter
Journal:  J Thromb Thrombolysis       Date:  2013-11       Impact factor: 2.300

6.  Explorative investigation of biomarkers of brain damage and coagulation system activation in clinical stroke differentiation.

Authors:  Johan Undén; Karin Strandberg; Jan Malm; Eric Campbell; Lars Rosengren; Johan Stenflo; Bo Norrving; Bertil Romner; Arne Lindgren; Gunnar Andsberg
Journal:  J Neurol       Date:  2009-02-09       Impact factor: 4.849

7.  Is protein C inhibitor antithrombotic and protective in pulmonary hypertension?

Authors:  L M Beaulieu; F C Church
Journal:  J Thromb Haemost       Date:  2006-09-15       Impact factor: 16.036

Review 8.  Serpins in thrombosis, hemostasis and fibrinolysis.

Authors:  J C Rau; L M Beaulieu; J A Huntington; F C Church
Journal:  J Thromb Haemost       Date:  2007-07       Impact factor: 5.824

9.  Phospholipid Binding Protein C Inhibitor (PCI) Is Present on Microparticles Generated In Vitro and In Vivo.

Authors:  Katrin Einfinger; Sigrun Badrnya; Margareta Furtmüller; Daniela Handschuh; Herbert Lindner; Margarethe Geiger
Journal:  PLoS One       Date:  2015-11-18       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.